Evidence map›Paper›PMID 40196374›Full record

ArticleFrontiers in pharmacology2025

Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of

Yunfan Dong, Zhaotao Duan, Min Liu, Yanbing Ding, Guangxia Chen, Ruifang Wang, Xiaodan Xu, Lixia Ding, Qiang Zhan, Chengyu Pan and 11 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05469685 (Efficacy and Safety of Vonoprazan- Amoxicillin Dual Therapy for Helicobacter Pylori Eradication), which is not on this map. Cited by 5 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05469685 phase4completednot on this map

Efficacy and Safety of Vonoprazan- Amoxicillin Dual Therapy for Helicobacter Pylori Eradication : a Prospective, Multicenter, Randomized Controlled Trial

TypeinterventionalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2022 to 2023Enrolled914ConditionsHelicobacter Pylori InfectionArmsVonoprazan, Amoxicillin
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yunfan DongDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zhaotao DuanDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Min LiuThe First People's Hospital of Xuzhou, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, China.
Yanbing DingDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Guangxia ChenThe First People's Hospital of Xuzhou, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, China.
Ruifang WangDepartment of Gastroenterology, Changshu No.1 People's Hospital, Suzhou, China.
Xiaodan XuDepartment of Gastroenterology, Changshu No.1 People's Hospital, Suzhou, China.
Lixia DingDepartments of Gastroenterology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Qiang ZhanDepartments of Gastroenterology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Chengyu PanAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Hui LiAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Faming YangDepartment of Gastroenterology, Taixing People's Hospital, Taixing, China.
Xiaorong DaiDepartment of Gastroenterology, Taixing People's Hospital, Taixing, China.
Xiangsu LiYancheng No.1 People's Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, China.
Xudong WuYancheng No.1 People's Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, China.
Peng PengDepartment of Gastroenterology, Taizhou Fourth People's Hospital, Taizhou, China.
Jianrong WangDepartment of Gastroenterology, Taizhou Fourth People's Hospital, Taizhou, China.
Kewei HuDepartment of Gastroenterology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Duanmin HuDepartment of Gastroenterology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Qiong JieDepartment of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zhenyu ZhangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the efficacy and cost-effectiveness of 10-day vonoprazan-amoxicillin (VA) dual therapy compared to 14-day VA therapy. Methods: A non-inferiority trial was carried out at 10 clinical centers to recruit patients with H. pylori infection. Subjects were assigned at random to either the group for 10-day or 14-day, and where given vonoprazan 20 mg bid and amoxicillin 1 g tid. Comparisons were made in terms of eradication rates, adverse events, cost-effectiveness, and compliance. Results: 914 participants were enrolled and randomly assigned to either the 10-day or 14-day VA groups. Using the intention-to-treat principle and multiple imputation for missing outcomes, the analysis showed an eradication rate of 88.79% in the 10-day group and 92.37% in the 14-day group (P = 0.064). The eradication rates were 89.14% and 93.35% by per-protocol analysis (P = 0.037). There were no significant differences in adverse events or compliance between the groups (P > 0.05). Logistic regression analysis indicated that smoking and prior failure of eradication were risk factors influencing the eradication rate (P < 0.05). For the economic evaluation, the cost-effectiveness ratio (CER) of the 10-day group was 426.30 yuan, the CER of the 14-day group was 485.27 yuan, and the incremental cost-effectiveness ratio was 1680.23 yuan. In probability sensitivity analysis, the cost-effectiveness acceptability curve showed that when the willingness-to-pay(WTP) threshold was below 1742 yuan, the 10-day group was more cost-effective. When the WTP threshold was above 1742 yuan, the 14-day group was more cost-effective. Conclusion: In this study, the 10-day VA was not found to be inferior to the 14-day VA. Compared with the 14-day group, the 10-day group is more cost-effective, but as the WTP threshold increases to 1742 yuan, the probability of the 14-day group being more cost-effective was greater than that of the 10-day group. Smoking and previous eradication attempts were associated with the eradication failure of VA therapy. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT05469685.

Indexed as

amoxicillincost-effectivenessdual therapyeradicationHelicobacter pylorivonoprazan

Identifiers

PMID40196374
PMCPMC11973372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.